ArticleHealth information science and systems2024
Supervised graph contrastive learning for cancer subtype identification through multi-omics data integration.
Article in Health information science and systems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- CAECC-Subtyper: A Novel Convolutional Autoencoder Framework for Integrating Multi-omics Data in Cancer Subtyping.Biochemical genetics · 2026Article
- Graph designs for deep learning-based multi-omics integration.Briefings in bioinformatics · 2026Review
- Robust graph structure learning to improve multi-omics cancer subtype classification.BMC bioinformatics · 2026Article
- X-intNMF: a cross- and intra-omics regularized NMF framework for multi-omics integration.Bioinformatics (Oxford, England) · 2026Article
- A multi-omics integration framework using multi-label guided learning and multi-scale fusion.Briefings in bioinformatics · 2025Article
- Using parenclitic networks on phaeochromocytoma and paraganglioma tumours provides novel insights on global DNA methylation.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the most deadly diseases in the world. Accurate cancer subtype classification is critical for patient diagnosis, treatment, and prognosis. Ever-increasing multi-omics data describes the characteristics of the patients from different views and serves as complementary information to promote cancer subtype identification. However, omics data generally have different distributions and high dimensions. How to effectively integrate multiple omics data to classify cancer subtypes accurately is a challenge for researchers. This work proposes a method integrating multi-omics data based on supervised graph contrast learning (MCRGCN) to classify cancer subtypes. The method considers the unique feature distribution of each omics data and the interaction of different omics data features to improve the accuracy of cancer subtype classification. To achieve this, MCRGCN first constructs different sample networks based on the multi-omics data of the samples. Then, it puts the omics data and adjacency matrix of the sample into different residual graph convolution models to get multi-omics features of the samples, which are trained with a supervised comparison loss to maintain that the sample features of each omics should be as consistent as possible. Finally, we input the sample features combining multi-omics features into a classifier to obtain the cancer subtypes. We applied MCRGCN to the invasive breast carcinoma (BRCA) and glioblastoma multiforme (GBM) datasets, integrating gene expression, miRNA expression, and DNA methylation data. The results demonstrate that our model is superior to other methods in integrating multi-omics data. Moreover, the results of survival analysis experiments demonstrate that the cancer subtypes identified by our model have significant clinical features. Furthermore, our model can help to identify potential biomarkers and pathways associated with cancer subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.